<DOC>
	<DOC>NCT00214994</DOC>
	<brief_summary>A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Tiagabine</mesh_term>
	<criteria>Subjects who have completed 10 weeks of doubleblind treatment and the subsequent taper period in 1 of the 3 previous doubleblind studies (studies C6671/3030/AX/US, C6671/3031/AX/US, or C6671/3032/AX/US).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>